While BMPR2, TBX4, and SMAD9 mutations have occasionally been identified in patients with PVOD-like features, they are exceedingly rare, and their clinical relevance remains limited in PVOD, contrasted to the central role of EIF2AK4 mutations. This evidence concerns the gene SMAD9 and pulmonary venoocclusive disease.